Opus Genetics (NASDAQ:IRD - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They currently have a $8.00 price objective on the stock.
Several other analysts have also commented on IRD. Jones Trading decreased their price objective on Opus Genetics from $9.00 to $8.00 and set a "buy" rating for the company in a report on Tuesday, April 1st. Wall Street Zen raised Opus Genetics from a "sell" rating to a "hold" rating in a research report on Thursday, May 22nd. Finally, Craig Hallum initiated coverage on Opus Genetics in a report on Friday, April 11th. They issued a "buy" rating and a $6.00 price target for the company.
Check Out Our Latest Research Report on Opus Genetics
Opus Genetics Stock Performance
IRD stock traded down $0.03 during trading on Friday, reaching $0.94. 289,099 shares of the company traded hands, compared to its average volume of 527,201. The business has a 50 day simple moving average of $0.96 and a 200 day simple moving average of $1.02. Opus Genetics has a 12 month low of $0.65 and a 12 month high of $1.75. The company has a market capitalization of $56.21 million and a price-to-earnings ratio of -0.45.
Opus Genetics (NASDAQ:IRD - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share for the quarter, beating analysts' consensus estimates of ($0.34) by $0.02. The business had revenue of $4.30 million for the quarter, compared to analysts' expectations of $4.00 million. Opus Genetics had a negative net margin of 429.42% and a negative return on equity of 283.28%. As a group, research analysts forecast that Opus Genetics will post -1.22 EPS for the current year.
Institutional Trading of Opus Genetics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. AWM Investment Company Inc. purchased a new position in shares of Opus Genetics in the first quarter worth about $515,000. Nantahala Capital Management LLC acquired a new position in Opus Genetics in the 1st quarter worth approximately $3,100,000. Royal Bank of Canada acquired a new position in Opus Genetics in the 1st quarter worth approximately $299,000. BIOS Capital Management LP purchased a new position in Opus Genetics during the 1st quarter worth approximately $977,000. Finally, Comerica Bank acquired a new stake in Opus Genetics during the 1st quarter valued at approximately $29,000. Institutional investors and hedge funds own 14.97% of the company's stock.
Opus Genetics Company Profile
(
Get Free Report)
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.
Recommended Stories
Before you consider Opus Genetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Opus Genetics wasn't on the list.
While Opus Genetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
